lazabemide has been researched along with Neurodegenerative Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baykov, S; Chirkova, Z; Engelbrecht, I; Korsakov, M; Osipyan, A; Petzer, A; Petzer, JP; Sapegin, A; Shetnev, A | 1 |
| Borroni, E; Cesura, AM; Gottowik, J; Kuhn, C; Malherbe, P; Martin, J; Richards, JG | 1 |
1 review(s) available for lazabemide and Neurodegenerative Diseases
| Article | Year |
|---|---|
Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.
Topics: Alzheimer Disease; Animals; Brain; Humans; Mice; Mice, Transgenic; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Oxidative Stress; Picolinic Acids | 1999 |
1 other study(ies) available for lazabemide and Neurodegenerative Diseases
| Article | Year |
|---|---|
Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework.
Topics: Dose-Response Relationship, Drug; Humans; Imidazoles; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Structure-Activity Relationship | 2019 |